PFE
$26.41
Pfizer
($.39)
(1.46%)
PFE
Earnings Whisper ®
N/A
4th Quarter December 2024
Consensus:  $0.48
Revenue:  $17.85 Bil
Tuesday
Feb 4
6:45 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when PFE reports earnings?
Beat
Meet
Miss

Where is PFE's stock price going from here?
Up
Flat
Down
Stock chart of PFE
Analysts
Summary of analysts' recommendations for PFE
Score
Grade
Pivots
Resistance
$27.36
$27.12
$26.76

$26.52

Support
$26.16
$25.92
$25.56
Tweet
Growth
Description
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Peers
Vertex PharmaceuticalsBioMarin PharmaceuticalARRAY TechnologiesRegeneron PharmaceuticalsMerck & Co.Bristol Myers SquibbEli LillyJohnson & JohnsonUltragenyx PharmaceuticalInsmed